Press Releases

Crinetics granted non-qualified stock option awards to purchase an aggregate of 258,800 shares of its common stock to twenty-seven new non-executive employees.

Crinetics announces the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $50.00 per share

Crinetics announces that it intends to offer and sell, subject to market and other conditions, $400.0 million of shares of its common stock in a proposed underwritten public offering.

Crinetics announces the submission of a New Drug Application to the FDA for its investigational drug, paltusotine, for the treatment of acromegaly.

Crinetics granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to fifteen new non-executive employees.